AU2002334433A1 - Method and pharmaceutical composition for inducing cancer cell-specific apoptosis by combination with tnf family proteins and flavopiridol - Google Patents

Method and pharmaceutical composition for inducing cancer cell-specific apoptosis by combination with tnf family proteins and flavopiridol

Info

Publication number
AU2002334433A1
AU2002334433A1 AU2002334433A AU2002334433A AU2002334433A1 AU 2002334433 A1 AU2002334433 A1 AU 2002334433A1 AU 2002334433 A AU2002334433 A AU 2002334433A AU 2002334433 A AU2002334433 A AU 2002334433A AU 2002334433 A1 AU2002334433 A1 AU 2002334433A1
Authority
AU
Australia
Prior art keywords
flavopiridol
combination
pharmaceutical composition
cancer cell
family proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002334433A
Inventor
Chang-Yong Hong
Shin-Wu Jeong
Dong-Myung Kim
Sung-Young Koo
Jin-Ho Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Chem Ltd
Original Assignee
LG Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LG Life Sciences Ltd filed Critical LG Life Sciences Ltd
Publication of AU2002334433A1 publication Critical patent/AU2002334433A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002334433A 2001-09-24 2002-09-19 Method and pharmaceutical composition for inducing cancer cell-specific apoptosis by combination with tnf family proteins and flavopiridol Abandoned AU2002334433A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020010059058A KR20030026069A (en) 2001-09-24 2001-09-24 Apoptosis-inducing cancer-cell-specific composition by combination with TNF family protein and flavopiridol
KR2001-0059058 2001-09-24
PCT/KR2002/001780 WO2003028001A2 (en) 2001-09-24 2002-09-19 Method and pharmaceutical composition for inducing cancer cell-specific apoptosis by combination with tnf family proteins and flavopiridol

Publications (1)

Publication Number Publication Date
AU2002334433A1 true AU2002334433A1 (en) 2003-04-07

Family

ID=19714614

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002334433A Abandoned AU2002334433A1 (en) 2001-09-24 2002-09-19 Method and pharmaceutical composition for inducing cancer cell-specific apoptosis by combination with tnf family proteins and flavopiridol

Country Status (3)

Country Link
KR (1) KR20030026069A (en)
AU (1) AU2002334433A1 (en)
WO (1) WO2003028001A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2356880B8 (en) 2009-08-21 2012-10-30 Universidad De Zaragoza LIPOSOMES COVERED WITH THE EXTRACELLULAR DOMAIN OF THE APO2L / TRAIL PROTEIN.
CN107205959B (en) * 2014-11-07 2021-02-12 大日本住友制药肿瘤学公司 Methods of targeting transcriptional control at a super-enhancer region
AU2016252609B2 (en) 2015-04-20 2022-06-30 Sumitomo Pharma Oncology, Inc. Predicting response to alvocidib by mitochondrial profiling
CN107849073B (en) 2015-05-18 2020-04-03 特雷罗药物股份有限公司 Avasidil prodrugs with increased bioavailability
KR20180034538A (en) 2015-08-03 2018-04-04 톨레로 파마수티컬스, 인크. Concurrent therapy for the treatment of cancer
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
MX2019007332A (en) 2016-12-19 2019-11-18 Tolero Pharmaceuticals Inc Profiling peptides and methods for sensitivity profiling.
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. Treatment regimen for cancers that are insensitive to bcl-2 inhibitors using the mcl-1 inhibitor alvocidib
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
CN110876741B (en) * 2019-11-25 2020-09-29 郑州大学第一附属医院 GBE1 inhibitor frataxin and application of pharmaceutical composition thereof in preparation of drugs for treating lung adenocarcinoma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980160A (en) * 1986-10-16 1990-12-25 Biogen, Inc. Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases
US6087366A (en) * 1996-03-07 2000-07-11 The Trustees Of Columbia University In The City Of New York Use of flavopiridol or a pharmaceutically acceptable salt thereof for inhibiting cell damage or cell death
US5750495A (en) * 1996-03-26 1998-05-12 The Regents Of The University Of California Treatment of cystic disease with TNF-α
CA2260216A1 (en) * 1996-07-15 1998-01-22 Bristol-Myers Squibb Company Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase

Also Published As

Publication number Publication date
WO2003028001A8 (en) 2003-05-08
WO2003028001A3 (en) 2003-12-04
WO2003028001A2 (en) 2003-04-03
KR20030026069A (en) 2003-03-31

Similar Documents

Publication Publication Date Title
WO2003073826A8 (en) Novel compositions and methods for cancer
AU2003262833A1 (en) Fluorescent glycosides and methods for their use
AU2002361623A1 (en) Methods and compositions for chromatography
AU2003229967A1 (en) Methods and compositions for cementing subterranean zones
AU2003207234A1 (en) Glass composition
AU2002334433A1 (en) Method and pharmaceutical composition for inducing cancer cell-specific apoptosis by combination with tnf family proteins and flavopiridol
AU2002364708A1 (en) Novel compositions and methods for cancer
AU2002334892A1 (en) Methods and compositions for mutation analysis by liquid chromatography
AU2003217219A1 (en) Nonlinear optical compounds and methods for their preparation
AU2003211884A1 (en) Sbn glass ceramic
EP1469769A4 (en) Novel compositions and methods for cancer
AU2003290939A1 (en) Replication of biological tiussue
AU2003268145A1 (en) Methods for propagating adenovirus and virus produced thereby
AU2002337943A1 (en) Novel compositions and methods for cancer
AU2003292441A1 (en) Temperature compensation improvements in radar apparatus
AU2003275476A1 (en) Cast collimator and method for making same
AU2001292301A1 (en) Novel drugs for liver diseases
EP1469870A4 (en) Novel compositions and methods for cancer
AU2002341828A1 (en) Enhanced proteins and methods for their use
AU2003281176A1 (en) Medicinal composition for mitigating blood lipid or lowering blood homocystein
AU2002259005A1 (en) Compositions and methods for inducing cancer cell death
EP1587405A4 (en) Novel compositions and methods for cancer
AU2003296568A1 (en) Portioned products comprising different constituents
AU2003235630A1 (en) Method for screening biological samples for presence of the metabolic syndrome
AU2574200A (en) Novel tnf receptor-like proteins

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase